Dabrafenib – Uses, Dosage, Side Effects, Interaction Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase and is used alone or in combination with trametinib in the treatment of advanced malignant melanoma. Dabrafenib therapy is associated with transient elevations in serum aminotransferase during therapy but has not been linked to instances of clinically apparent acute liver injury. Dabrafenib is an orally bioavailable inhibitor of the B-RAF (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. Dabrafenib is an organofluorine compound and antineoplastic agent, used as its mesylate salt in the treatment of metastatic melanoma. It has a role as an antineoplastic agent, a B-Raf inhibitor, and an anticoronaviral agent. It is a sulfonamide, an organofluorine compound, a member of 1,3-thiazoles, and an aminopyrimidine. Dabrafenib mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma. It has a role as an antineoplastic agent and a B-Raf inhibitor. It contains a dabrafenib. Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-RAF (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. Mechanism of Action Dabrafenib is an orally bioavailable inhibitor of B-RAF (BRAF) protein with antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/Extracellular Signal-regulated Kinases signaling pathway, which may be constitutively activated due to BRAF gene mutations. Dabrafenib causes inhibition of phosphorylated extracellular signal-regulated kinase (ERK). This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited. The melanoma approval for use with Mekinist is based on results from COMBI-AD, a Phase III study of 870 patients with Stage III BRAF V600E/K mutation-positive melanoma treated with Tafinlar + Mekinist after complete surgical resection. Patients received doses of Tafinlar (150 mg BID) + Mekinist (2 mg QD) combination (n = 438) or matching placebos (n = 432). After a median follow-up of 2.8 years, the primary endpoint of relapse-free survival (RFS) was met. Thus, Tafinlar in combination with Mekinist treats melanoma. In the case of thyroid cancer, Dabrafenib plus Trametinib is the first regimen demonstrated to have potent clinical activity in BRAF V600E–mutated anaplastic thyroid cancer and is well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease. Indications Tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of a durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib. In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. Melanoma – Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Adjuvant treatment of melanoma – Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) – Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. Non-small cell lung cancer (NSCLC) – Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation Treatment of melanoma, Treatment of solid malignant tumors (excluding melanoma) Dabrafenib was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.[rx] Later, it was used in combination with trametinib for the treatment of unresectable or metastatic melanoma with V600E or V600K mutations, either as primary treatment or adjuvant treatment.[rx] Metastatic Anaplastic Thyroid Cancer Metastatic Melanoma Metastatic Non-Small Cell Lung Cancer Unresectable Melanoma Unresectable or Metastatic Solid Tumors Locally advanced Thyroid Cancer, Anaplastic Use in Cancer Dabrafenib mesylate is approved to be used alone or with trametinib to treat patients whose cancer has a certain mutation in the BRAF gene, including: Anaplastic thyroid cancer is locally advanced or has spread to other parts of the body and cannot be treated with local therapy. It is used with trametinib. Melanoma. It is used: Trametinib in patients who have had surgery to remove cancer that has spread to the lymph nodes. Alone or with trametinib in patients whose cancer cannot be removed by surgery or has spread to other parts of the body. Non-small cell lung cancer that has metastasized. It is used with trametinib. Solid tumors. It is used with trametinib in adults and children aged 6 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body and have gotten worse after other treatments and cannot be treated with other therapies.¹ This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that dabrafenib mesylate provides a clinical benefit in these patients. Dabrafenib mesylate is also being studied in the treatment of other types of cancer. Contraindications Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC squamous cell carcinoma diabetes inflammation of the iris – the colored part of the eyeball inflammation of the uvea of the eye chronic heart failure abnormal EKG with QT changes from birth bleeding a body temperature higher than 101 degrees Fahrenheit pregnancy a patient who is producing milk and breastfeeding basal cell carcinoma of the skin anemia from pyruvate kinase and G6PD deficiencies a type of slow growing skin cancer called a keratoacanthoma progression of cancer with the RAS mutation Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 75 mg; 50 mg Non-Small Cell Lung Cancer 150 mg orally 2 times a day, either as monotherapy or in combination with trametinib Duration of Therapy: Until disease progression or unacceptable toxicity occurs Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test. Take doses approximately 12 hours apart. Take this drug at least 1 hour before or 2 hours after a meal. Do not take a missed dose within 6 hours of the next dose. Do not open, crush, or break capsules. As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options Melanoma – Metastatic 150 mg orally 2 times a day, either as monotherapy or in combination with trametinib Duration of Therapy: Until disease progression or unacceptable toxicity occurs Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test. Take doses approximately 12 hours apart. Take this drug at least 1 hour before or 2 hours after a meal. Do not take a missed dose within 6 hours of the next dose. Do not open, crush, or break capsules. As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options Thyroid Cancer 150 mg orally 2 times a day, either as monotherapy or in combination with trametinib Duration of Therapy: Until disease progression or unacceptable toxicity occurs Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test. Take doses approximately 12 hours apart. Take this drug at least 1 hour before or 2 hours after a meal. Do not take a missed dose within 6 hours of the next dose. Do not open, crush, or break capsules. As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options For Oral For oral dosage form (capsules): For melanoma (skin cancer), non-small cell lung cancer, anaplastic thyroid cancer, and solid tumors: Adults—150 milligrams (mg) 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated. Children 6 years of age and older—The dose is based on body weight and must be determined by your doctor. Weighing 51 kilograms (kg) or more—150 milligrams (mg) 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated. Weighing 38 to 50 kg—100 mg 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated. Weighing 26 to 37 kg—75 mg 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated. Children younger than 6 years of age—Use and dose must be determined by your doctor. Dose Adjustments DOSE REDUCTIONS FOR ADVERSE REACTIONS: First Dose Reduction: 100 mg twice a day Second Dose Reduction: 75 mg twice a day Third Dose Reduction: 50 mg twice a day Subsequent Modification: Permanently discontinue treatment if unable to tolerate 50 mg twice a day. For New Primary Cutaneous Malignancies that develop: No dose modifications are recommended. For New Primary Non-Cutaneous Malignancies: Permanently discontinue in patients who develop RAS mutation-positive non-cutaneous malignancies. Fever 101.3F to 104F: Withhold dabrafenib until the adverse reaction resolves, then resume at the same dose or at a reduced level. NEW PRIMARY CUTANEOUS MALIGNANCIES: No adjustment is recommended. NEW PRIMARY NON-CUTANEOUS MALIGNANCIES: Permanently discontinue treatment in patients who develop RAS mutation-positive non-cutaneous malignancies. CARDIAC: Symptomatic Congestive Heart Failure; Absolute Decrease in Left Ventricular Ejection Fraction [LVEF] of Greater Than 20% from Baseline that is Below Lower Level of Normal [LLN]): Withhold treatment, then resume at the same dose upon recovery of cardiac function. PYREXIA: Fever of 101.3 to 104 Degrees Fahrenheit: Withhold treatment until fever resolves, then resume at the same or lower dose level. Fever Higher Than 104 Degrees Fahrenheit; Fever Complicated by Rigors, Hypotension, Dehydration, or Renal Failure: Withhold treatment until fever resolves, then resume at a lower dose level OR permanently discontinue treatment. SKIN TOXICITY (Intolerable Grade 2, Grade 3, or Grade 4): Withhold treatment for up to 3 weeks If Improved: Resume at a lower dose. If Not Improved: Permanently discontinue treatment. UVEITIS (Severe OR Mild/Moderate that Does Not Respond to Ocular Therapy): Withhold treatment for up to 6 weeks. If Improved to Grade 0 to 1: Resume at same or lower dose level. If Not Improved: Permanently discontinue treatment. OTHER ADVERSE REACTIONS: INTOLERABLE GRADE 2; ANY GRADE 3: Withhold treatment. If Improved to Grade 0 to 1: Resume at a lower dose level. If Not Improved: Permanently discontinue treatment. FIRST OCCURRENCE OF ANY GRADE 4: Withhold treatment until improvement to Grade 0 to 1, then resume at a lower dose level OR permanently discontinue treatment. RECURRENT GRADE 4: Permanently discontinue treatment. Comments: Dose adjustments are NOT recommended for this drug when it is administered in combination with trametinib for the following adverse reactions: retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), interstitial lung disease (ILD)/pneumonitis, and uncomplicated venous thromboembolism. Consult the manufacturer’s product information for trametinib dosing recommendations. Administration Advice: Direct patients to take this drug at least 1 hour before or 2 hours after a meal, and at similar times every day with an interval of approximately 12 hours between doses. Instruct patients to swallow drug capsules whole with water, and not to open, crush, chew, or break capsules. Warn patients not to mix capsule contents with food or liquids due to the chemical instability of this drug. Advise patients not to take a missed dose within 6 hours of the next scheduled dose. In the event of a vomited dose, counsel patients not to retake that dose and to resume dosing with the next scheduled dose. Consult the manufacturer product information for trametinib dosing recommendations prior to initiation of combination treatment with this drug. Side Effects The Most Common headache joint, muscle, or back pain nausea diarrhea constipation loss of appetite cough, runny nose, or sore throat hair loss tiredness changes in skin (new wart, skin sore, or red bump that bleeds or does not heal) change in size or color of a mole rash, red skin, or pimples fever fainting dizziness, lightheadedness, or weakness chills decreased urination swelling of hands, feet, ankles, or lower legs frequent urination increased thirst eye pain red or swollen eyelids sensitivity to light blurred vision or vision changes, including seeing halos (blurred outline around objects) or colored dots swelling, pain, redness, or peeling of skin on the palms and soles of the feet ongoing pain that begins in the stomach area but may spread to the back unusual bleeding or bruising bloody or black, tarry stools coughing up or vomiting blood or material that looks like coffee grounds chest pain shortness of breath swelling of the hands, feet, ankles or lower legs fast, irregular, or pounding heartbeat yellowing of the skin and eyes More common Bleeding gums bloody, black, or tarry stools bloody or cloudy urine blurred vision coughing up blood difficulty in breathing or swallowing dizziness dry mouth fever flushed, dry skin fruit-like breath odor greatly decreased frequency of urination or amount of urine headache heartburn increased hunger increased thirst increased urination indigestion lump or growth on the skin nausea nosebleed prolonged bleeding from cuts red or black, tarry stools red or dark brown urine redness, swelling, or pain of the skin scaling of the skin on the hands and feet skin blisters skin rash stomach pain or cramps sweating swelling of the feet or lower legs tingling of the hands and feet ulceration of the skin unable to move unexplained weight loss unusual tiredness or weakness vomiting vomiting of material that looks like coffee grounds, severe and continuing Rare Blurred vision or other change in vision change in color vision difficulty seeing at night eye pain increased sensitivity of the eyes to sunlight redness of the eye tearing Blistering, peeling, loosening of the skin chills cough diarrhea itching joint or muscle pain red skin lesions, often with a purple center sore throat sores, ulcers, or white spots in the mouth or on lips swollen, painful, or tender lymph glands in the neck, armpit, or groin yellow eyes or skin Drug Interaction DRUG INTERACTION Benzodiazepine The serum concentration of 1,2-Benzodiazepine can be decreased when it is combined with Dabrafenib. Abacavir The metabolism of Abacavir can be decreased when combined with Dabrafenib. Abametapir The serum concentration of Dabrafenib can be increased when it is combined with Abametapir. Abatacept The metabolism of Dabrafenib can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with Dabrafenib. Abiraterone The serum concentration of Abiraterone can be decreased when it is combined with Dabrafenib. Abrocitinib The metabolism of Abrocitinib can be increased when combined with Dabrafenib. Acalabrutinib The serum concentration of Acalabrutinib can be decreased when it is combined with Dabrafenib. Acamprosate The excretion of Acamprosate can be decreased when combined with Dabrafenib. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Dabrafenib. Acenocoumarol The serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib. Acetaminophen The serum concentration of Acetaminophen can be decreased when it is combined with Dabrafenib. Acetazolamide The metabolism of Dabrafenib can be decreased when combined with Acetazolamide. Acetohexamide The serum concentration of Acetohexamide can be decreased when it is combined with Dabrafenib. Acetyl sulfisoxazole The metabolism of Dabrafenib can be decreased when combined with Acetyl sulfisoxazole. Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib. Acrivastine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Acrivastine. Acyclovir The excretion of Acyclovir can be decreased when combined with Dabrafenib. Adalimumab The metabolism of Dabrafenib can be increased when combined with Adalimumab. Adefovir dipivoxil The excretion of Adefovir dipivoxil can be decreased when combined with Dabrafenib. Adenosine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Adenosine. Afatinib The serum concentration of Dabrafenib can be increased when it is combined with Afatinib. Agomelatine The metabolism of Dabrafenib can be decreased when combined with Agomelatine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Dabrafenib. Albendazole The serum concentration of Albendazole can be decreased when it is combined with Dabrafenib. Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Dabrafenib. Alclometasone The serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib. Aldesleukin The metabolism of Dabrafenib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be increased when combined with Dabrafenib. Alfentanil The serum concentration of Alfentanil can be decreased when it is combined with Dabrafenib. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Dabrafenib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Dabrafenib. Aliskiren The serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib. Allopurinol The excretion of Allopurinol can be decreased when combined with Dabrafenib. Almasilate Almasilate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Almotriptan The serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib. Alogliptin The serum concentration of Alogliptin can be decreased when it is combined with Dabrafenib. Alosetron The serum concentration of Alosetron can be decreased when it is combined with Dabrafenib. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Dabrafenib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Dabrafenib. Alprostadil The excretion of Alprostadil can be decreased when combined with Dabrafenib. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Amantadine The serum concentration of Amantadine can be increased when it is combined with Dabrafenib. Ambrisentan The serum concentration of Ambrisentan can be decreased when it is combined with Dabrafenib. Ambroxol The serum concentration of Ambroxol can be decreased when it is combined with Dabrafenib. Amcinonide The serum concentration of Amcinonide can be decreased when it is combined with Dabrafenib. Amifampridine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Amifampridine. Aminoglutethimide The metabolism of Dabrafenib can be increased when combined with Aminoglutethimide. Aminohippuric acid The excretion of Aminohippuric acid can be decreased when combined with Dabrafenib. Aminophenazone The serum concentration of Aminophenazone can be decreased when it is combined with Dabrafenib. Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib. Amiodarone The serum concentration of Dabrafenib can be increased when it is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Dabrafenib. Amitriptyline The serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib. Amlodipine The metabolism of Amlodipine can be increased when combined with Dabrafenib. Amobarbital The metabolism of Dabrafenib can be increased when combined with Amobarbital. Amodiaquine The serum concentration of Amodiaquine can be decreased when it is combined with Dabrafenib. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Dabrafenib. Amprenavir The serum concentration of Dabrafenib can be increased when it is combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Anagrelide. Anakinra The metabolism of Dabrafenib can be increased when combined with Anakinra. Anastrozole The serum concentration of Anastrozole can be decreased when it is combined with Dabrafenib. Antazoline The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Antazoline. Antipyrine The serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib. Apalutamide The serum concentration of Apalutamide can be increased when it is combined with Dabrafenib. Apixaban The serum concentration of Apixaban can be decreased when it is combined with Dabrafenib. Apomorphine The serum concentration of Apomorphine can be decreased when it is combined with Dabrafenib. Apremilast The serum concentration of Apremilast can be decreased when it is combined with Dabrafenib. Aprepitant The serum concentration of Aprepitant can be decreased when it is combined with Dabrafenib. Arformoterol The serum concentration of Arformoterol can be decreased when it is combined with Dabrafenib. Aripiprazole The serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib. Aripiprazole The serum concentration of Aripiprazole lauroxil can be decreased when it is combined with Dabrafenib. Armodafinil The metabolism of Dabrafenib can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Dabrafenib can be increased when it is combined with Arsenic trioxide. Artemether The serum concentration of Artemether can be decreased when it is combined with Dabrafenib. Articaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Articaine. Asciminib The serum concentration of Dabrafenib can be increased when it is combined with Asciminib. Asenapine The serum concentration of Asenapine can be decreased when it is combined with Dabrafenib. Astemizole The serum concentration of Astemizole can be decreased when it is combined with Dabrafenib. Asunaprevir The serum concentration of Asunaprevir can be decreased when it is combined with Dabrafenib. Atazanavir The serum concentration of Dabrafenib can be increased when it is combined with Atazanavir. Atogepant The serum concentration of Atogepant can be increased when it is combined with Dabrafenib. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dabrafenib. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Dabrafenib. Atovaquone The serum concentration of Atovaquone can be decreased when it is combined with Dabrafenib. Atropine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Atropine. Avacopan The serum concentration of Avacopan can be decreased when it is combined with Dabrafenib. Avanafil The serum concentration of Avanafil can be decreased when it is combined with Dabrafenib. Avapritinib The serum concentration of Avapritinib can be decreased when it is combined with Dabrafenib. Avatrombopag The metabolism of Dabrafenib can be increased when combined with Avatrombopag. Avibactam The excretion of Avibactam can be decreased when combined with Dabrafenib. Axitinib The serum concentration of Axitinib can be decreased when it is combined with Dabrafenib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dabrafenib. Azelastine The serum concentration of Azelastine can be decreased when it is combined with Dabrafenib. Azithromycin The serum concentration of Azithromycin can be decreased when it is combined with Dabrafenib. Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Dabrafenib. Bazedoxifene The metabolism of Bazedoxifene can be decreased when combined with Dabrafenib. Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Dabrafenib. Bedaquiline The serum concentration of Bedaquiline can be decreased when it is combined with Dabrafenib. Belantamab The serum concentration of Dabrafenib can be increased when it is combined with Belantamab mafodotin. Belinostat The metabolism of Belinostat can be decreased when combined with Dabrafenib. Belumosudil The serum concentration of Belumosudil can be decreased when it is combined with Dabrafenib. Belzutifan The serum concentration of Dabrafenib can be decreased when it is combined with Belzutifan. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Dabrafenib. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Dabrafenib. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dabrafenib. Benzocaine The serum concentration of Benzocaine can be decreased when it is combined with Dabrafenib. Benzphetamine The serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib. Benzyl alcohol The serum concentration of Benzyl alcohol can be decreased when it is combined with Dabrafenib. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Dabrafenib. Bepridil The serum concentration of Bepridil can be decreased when it is combined with Dabrafenib. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Dabrafenib. Betamethasone The serum concentration of Betamethasone can be decreased when it is combined with Dabrafenib. Betamethasone phosphate The serum concentration of Betamethasone phosphate can be decreased when it is combined with Dabrafenib. Betrixaban The serum concentration of Dabrafenib can be increased when it is combined with Betrixaban. Bexarotene The serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib. Bezafibrate The serum concentration of Bezafibrate can be decreased when it is combined with Dabrafenib. Bicalutamide The serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib. Bictegravir The serum concentration of Bictegravir can be decreased when it is combined with Dabrafenib. Bifonazole The metabolism of Dabrafenib can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Bilastine. Bimekizumab The metabolism of Dabrafenib can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Dabrafenib. Bioallethrin The serum concentration of Bioallethrin can be decreased when it is combined with Dabrafenib. Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Bisoprolol The serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib. Boceprevir The serum concentration of Dabrafenib can be increased when it is combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib. Bosentan The serum concentration of Bosentan can be decreased when it is combined with Dabrafenib. Bosutinib The serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Dabrafenib. Brexpiprazole The serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib. Brigatinib The serum concentration of Brigatinib can be decreased when it is combined with Dabrafenib. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Dabrafenib. Brinzolamide The serum concentration of Brinzolamide can be decreased when it is combined with Dabrafenib. Brivaracetam The serum concentration of Brivaracetam can be decreased when it is combined with Dabrafenib. Bromocriptine The serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib. Brompheniramine The serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dabrafenib. Budesonide The serum concentration of Budesonide can be decreased when it is combined with Dabrafenib. Bumetanide The excretion of Bumetanide can be decreased when combined with Dabrafenib. Bupivacaine The serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib. Buprenorphine The serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib. Bupropion The serum concentration of Bupropion can be decreased when it is combined with Dabrafenib. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Dabrafenib. Buspirone The serum concentration of Buspirone can be decreased when it is combined with Dabrafenib. Busulfan The serum concentration of Busulfan can be decreased when it is combined with Dabrafenib. Butacaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Butacaine. Butalbital The metabolism of Dabrafenib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Butriptyline. Cabazitaxel The serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib. Cabergoline The serum concentration of Cabergoline can be decreased when it is combined with Dabrafenib. Cabotegravir The metabolism of Cabotegravir can be decreased when combined with Dabrafenib. Cabozantinib The serum concentration of Cabozantinib can be decreased when it is combined with Dabrafenib. Caffeine Caffeine may decrease the excretion rate of Dabrafenib which could result in a higher serum level. Calcitriol The serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Canagliflozin The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib. Canakinumab The metabolism of Dabrafenib can be increased when combined with Canakinumab. Candesartan cilexetil The serum concentration of Dabrafenib can be increased when it is combined with Candesartan cilexetil. Candicidin The metabolism of Dabrafenib can be decreased when combined with Candicidin. Cannabidiol The serum concentration of Cannabidiol can be decreased when it is combined with Dabrafenib. Capecitabine The metabolism of Capecitabine can be decreased when combined with Dabrafenib. Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Dabrafenib. Capsaicin The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Capsaicin. Captopril The excretion of Captopril can be decreased when combined with Dabrafenib. Carbamazepine The serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib. Carbinoxamine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Carbinoxamine. Carfilzomib The serum concentration of Dabrafenib can be increased when it is combined with Carfilzomib. Cariprazine The serum concentration of Cariprazine can be decreased when it is combined with Dabrafenib. Carisoprodol The serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib. Carvedilol The serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib. Caspofungin The excretion of Caspofungin can be decreased when combined with Dabrafenib. Cefaclor The excretion of Cefaclor can be decreased when combined with Dabrafenib. Cefazolin The excretion of Cefazolin can be decreased when combined with Dabrafenib. Cefdinir The excretion of Cefdinir can be decreased when combined with Dabrafenib. Cefotiam The excretion of Cefotiam can be decreased when combined with Dabrafenib. Cefradine The metabolism of Dabrafenib can be increased when combined with Cefradine. Ceftibuten The excretion of Ceftibuten can be decreased when combined with Dabrafenib. Ceftizoxime The excretion of Ceftizoxime can be decreased when combined with Dabrafenib. Celecoxib The serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Dabrafenib. Cenobamate The serum concentration of Cenobamate can be decreased when it is combined with Dabrafenib. Cephalexin The serum concentration of Cephalexin can be decreased when it is combined with Dabrafenib. Ceritinib The serum concentration of Ceritinib can be decreased when it is combined with Dabrafenib. Cerivastatin The serum concentration of Cerivastatin can be decreased when it is combined with Dabrafenib. Certolizumab pegol The metabolism of Dabrafenib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Dabrafenib. Cevimeline The serum concentration of Cevimeline can be decreased when it is combined with Dabrafenib. Chenodeoxycholic acid The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dabrafenib. Chloramphenicol The metabolism of Dabrafenib can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Chlorcyclizine. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Chloroprocaine. Chloroquine The serum concentration of Chloroquine can be decreased when it is combined with Dabrafenib. Chlorpheniramine The serum concentration of Chlorpheniramine can be decreased when it is combined with Dabrafenib. Chlorpromazine The serum concentration of Chlorpromazine can be decreased when it is combined with Dabrafenib. Chlorpropamide The serum concentration of Chlorpropamide can be decreased when it is combined with Dabrafenib. You Might Also Read Tapentadol Contraindications, Pregnancy Category Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Dabrafenib. Chlorzoxazone The serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib. Cholecalciferol The serum concentration of Cholecalciferol can be decreased when it is combined with Dabrafenib. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Dabrafenib. Cholesterol Cholesterol may increase the excretion rate of Dabrafenib which could result in a lower serum level and potentially a reduction in efficacy. Cholic Acid The excretion of Cholic Acid can be decreased when combined with Dabrafenib. Choline The serum concentration of Choline can be increased when it is combined with Dabrafenib. Choline salicylate The serum concentration of Choline salicylate can be increased when it is combined with Dabrafenib. Ciclesonide The serum concentration of Ciclesonide can be decreased when it is combined with Dabrafenib. Cidofovir The excretion of Cidofovir can be decreased when combined with Dabrafenib. Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Dabrafenib. Cimetidine Cimetidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinacalcet The serum concentration of Cinacalcet can be decreased when it is combined with Dabrafenib. Cinchocaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Cinchocaine. Cinnarizine The serum concentration of Cinnarizine can be decreased when it is combined with Dabrafenib. Cinoxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Cinoxacin. Ciprofloxacin The metabolism of Dabrafenib can be decreased when combined with Ciprofloxacin. Cisapride The serum concentration of Cisapride can be decreased when it is combined with Dabrafenib. Cisplatin The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib. Citalopram The serum concentration of Citalopram can be decreased when it is combined with Dabrafenib. Cladribine Dabrafenib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The serum concentration of Dabrafenib can be increased when it is combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Clemastine. Clevidipine The serum concentration of Clevidipine can be decreased when it is combined with Dabrafenib. Clindamycin The metabolism of Clindamycin can be increased when combined with Dabrafenib. Clobazam The serum concentration of Clobazam can be decreased when it is combined with Dabrafenib. Clobetasol The serum concentration of Clobetasol can be decreased when it is combined with Dabrafenib. Clobetasol propionate The serum concentration of Clobetasol propionate can be decreased when it is combined with Dabrafenib. Clobetasone The serum concentration of Clobetasone can be decreased when it is combined with Dabrafenib. Clofarabine The serum concentration of Clofarabine can be increased when it is combined with Dabrafenib. Clofazimine The serum concentration of Dabrafenib can be increased when it is combined with Clofazimine. Clofibrate The serum concentration of Clofibrate can be decreased when it is combined with Dabrafenib. Clomifene The serum concentration of Dabrafenib can be increased when it is combined with Clomifene. Clomipramine The serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib. Clonazepam The metabolism of Clonazepam can be increased when combined with Dabrafenib. Clonidine The serum concentration of Clonidine can be decreased when it is combined with Dabrafenib. Clopidogrel The serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib. Clorazepic acid The serum concentration of Clorazepic acid can be decreased when it is combined with Dabrafenib. Clotiazepam The serum concentration of Clotiazepam can be decreased when it is combined with Dabrafenib. Clozapine The serum concentration of Clozapine can be decreased when it is combined with Dabrafenib. Cobicistat The serum concentration of Dabrafenib can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be decreased when it is combined with Dabrafenib. Cocaine The serum concentration of Cocaine can be decreased when it is combined with Dabrafenib. Codeine The serum concentration of Codeine can be decreased when it is combined with Dabrafenib. Colchicine The metabolism of Colchicine can be decreased when combined with Dabrafenib. Conivaptan The serum concentration of Dabrafenib can be increased when it is combined with Conivaptan. Conjugated estrogens The serum concentration of Conjugated estrogens can be decreased when it is combined with Dabrafenib. Copanlisib The serum concentration of Copanlisib can be decreased when it is combined with Dabrafenib. Corticotropin The serum concentration of Corticotropin can be decreased when it is combined with Dabrafenib. Cortisone acetate The serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib. Crizotinib The metabolism of Dabrafenib can be decreased when combined with Crizotinib. Curcumin The serum concentration of Dabrafenib can be increased when it is combined with Curcumin. Cyclandelate The serum concentration of Cyclandelate can be decreased when it is combined with Dabrafenib. Cyclizine The metabolism of Dabrafenib can be decreased when combined with Cyclizine. Cyclobenzaprine The serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib. Cyclophosphamide The serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib. Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Dabrafenib. Cyproterone acetate The serum concentration of Cyproterone acetate can be decreased when it is combined with Dabrafenib. Dabigatran etexilate The serum concentration of Dabrafenib can be increased when it is combined with Dabigatran etexilate. Daclatasvir The serum concentration of Daclatasvir can be decreased when it is combined with Dabrafenib. Dacomitinib The serum concentration of Dacomitinib can be decreased when it is combined with Dabrafenib. Dactinomycin Dabrafenib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dalfampridine The serum concentration of Dalfampridine can be increased when it is combined with Dabrafenib. Dalfopristin The metabolism of Dabrafenib can be decreased when combined with Dalfopristin. Danazol The serum concentration of Dabrafenib can be increased when it is combined with Danazol. Dapagliflozin The serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib. Dapsone The serum concentration of Dapsone can be decreased when it is combined with Dabrafenib. Daptomycin The serum concentration of Dabrafenib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dabrafenib. Daridorexant The serum concentration of Daridorexant can be decreased when it is combined with Dabrafenib. Darifenacin The serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib. Darolutamide The serum concentration of Dabrafenib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Dabrafenib can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Dasabuvir can be decreased when it is combined with Dabrafenib. Dasatinib The serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib. Daunorubicin The metabolism of Dabrafenib can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Dabrafenib can be increased when combined with Deferasirox. Deflazacort The serum concentration of Deflazacort can be decreased when it is combined with Dabrafenib. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dabrafenib. Delafloxacin The metabolism of Dabrafenib can be increased when combined with Delafloxacin. Delamanid The serum concentration of Delamanid can be decreased when it is combined with Dabrafenib. Delavirdine The serum concentration of Dabrafenib can be increased when it is combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dabrafenib. Desipramine The metabolism of Dabrafenib can be decreased when combined with Desipramine. Desloratadine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Desloratadine. Desogestrel The serum concentration of Desogestrel can be decreased when it is combined with Dabrafenib. Desonide The serum concentration of Desonide can be decreased when it is combined with Dabrafenib. Desoxycorticosterone The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Dabrafenib. Desvenlafaxine The serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib. Deutetrabenazine The serum concentration of Deutetrabenazine can be decreased when it is combined with Dabrafenib. Dexamethasone The serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib. Dexamethasone The serum concentration of Dexamethasone acetate can be decreased when it is combined with Dabrafenib. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dabrafenib. Dexchlorpheniramine The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Dabrafenib. Dexibuprofen The serum concentration of Dexibuprofen can be decreased when it is combined with Dabrafenib. Dexlansoprazole The serum concentration of Dexlansoprazole can be decreased when it is combined with Dabrafenib. Dextromethorphan The serum concentration of Dextromethorphan can be decreased when it is combined with Dabrafenib. Dextropropoxyphene The serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib. Diacerein The metabolism of Dabrafenib can be decreased when combined with Diacerein. Diazepam The serum concentration of Diazepam can be decreased when it is combined with Dabrafenib. Diclofenac The serum concentration of Diclofenac can be decreased when it is combined with Dabrafenib. Dicloxacillin The metabolism of Dabrafenib can be increased when combined with Dicloxacillin. Dicoumarol The serum concentration of Dicoumarol can be decreased when it is combined with Dabrafenib. Didanosine The excretion of Didanosine can be decreased when combined with Dabrafenib. Dienogest The serum concentration of Dienogest can be decreased when it is combined with Dabrafenib. Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabrafenib. Difluocortolone The serum concentration of Difluocortolone can be decreased when it is combined with Dabrafenib. Difluprednate The serum concentration of Difluprednate can be decreased when it is combined with Dabrafenib. Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dabrafenib. Dihydro-alpha The serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Dabrafenib. Dihydrocodeine The serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib. Dihydroergocornine The serum concentration of Dihydroergocornine can be decreased when it is combined with Dabrafenib. Dihydroergocristine The serum concentration of Dihydroergocristine can be decreased when it is combined with Dabrafenib. Dihydroergotamine The serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib. Diltiazem The serum concentration of Diltiazem can be decreased when it is combined with Dabrafenib. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dimenhydrinate. Dimethyl sulfoxide The metabolism of Dabrafenib can be decreased when combined with Dimethyl sulfoxide. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Dabrafenib. Diosmin The serum concentration of Dabrafenib can be increased when it is combined with Diosmin. Diphenhydramine The serum concentration of Diphenhydramine can be decreased when it is combined with Dabrafenib. Disopyramide The serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib. Disulfiram The serum concentration of Disulfiram can be decreased when it is combined with Dabrafenib. Docetaxel The serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib. Doconexent The serum concentration of Doconexent can be decreased when it is combined with Dabrafenib. Dofetilide The serum concentration of Dofetilide can be decreased when it is combined with Dabrafenib. Dolasetron The serum concentration of Dolasetron can be decreased when it is combined with Dabrafenib. Dolutegravir Dabrafenib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The serum concentration of Domperidone can be decreased when it is combined with Dabrafenib. Donepezil The serum concentration of Donepezil can be decreased when it is combined with Dabrafenib. Dopamine The serum concentration of Dopamine can be increased when it is combined with Dabrafenib. Doravirine The serum concentration of Doravirine can be decreased when it is combined with Dabrafenib. Doripenem The excretion of Doripenem can be decreased when combined with Dabrafenib. Dosulepin The serum concentration of Dosulepin can be decreased when it is combined with Dabrafenib. Doxazosin The serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib. Doxepin The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib. Doxorubicin The serum concentration of Doxorubicin can be decreased when it is combined with Dabrafenib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dabrafenib. Dronabinol The serum concentration of Dronabinol can be decreased when it is combined with Dabrafenib. Dronedarone The serum concentration of Dabrafenib can be increased when it is combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Droperidol. Drospirenone The serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib. Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dabrafenib. Duloxetine The serum concentration of Duloxetine can be decreased when it is combined with Dabrafenib. Duvelisib The serum concentration of Duvelisib can be decreased when it is combined with Dabrafenib. Dyclonine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Dyclonine. Dydrogesterone The serum concentration of Dydrogesterone can be decreased when it is combined with Dabrafenib. Ebastine The serum concentration of Ebastine can be decreased when it is combined with Dabrafenib. Echinacea The metabolism of Dabrafenib can be increased when combined with Echinacea. Econazole The serum concentration of Dabrafenib can be increased when it is combined with Econazole. Edoxaban The serum concentration of Dabrafenib can be increased when it is combined with Edoxaban. Efavirenz The serum concentration of Dabrafenib can be increased when it is combined with Efavirenz. Elagolix The serum concentration of Elagolix can be decreased when it is combined with Dabrafenib. Elbasvir The serum concentration of Elbasvir can be decreased when it is combined with Dabrafenib. Eletriptan The serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib. Elexacaftor The serum concentration of Elexacaftor can be decreased when it is combined with Dabrafenib. Eliglustat The metabolism of Eliglustat can be decreased when combined with Dabrafenib. Eltrombopag The serum concentration of Eltrombopag can be decreased when it is combined with Dabrafenib. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Dabrafenib. Elvitegravir The serum concentration of Dabrafenib can be increased when it is combined with Elvitegravir. Emapalumab The metabolism of Dabrafenib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Emedastine. Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib. Enalapril The excretion of Enalapril can be decreased when combined with Dabrafenib. Enasidenib The serum concentration of Enasidenib can be decreased when it is combined with Dabrafenib. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Dabrafenib. Encorafenib The serum concentration of Encorafenib can be decreased when it is combined with Dabrafenib. Enfortumab vedotin The serum concentration of Enfortumab vedotin can be decreased when it is combined with Dabrafenib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dabrafenib. Entrectinib The metabolism of Entrectinib can be increased when combined with Dabrafenib. Enzalutamide The serum concentration of Enzalutamide can be increased when it is combined with Dabrafenib. Epinastine The serum concentration of Epinastine can be decreased when it is combined with Dabrafenib. Epinephrine The metabolism of Dabrafenib can be decreased when combined with Epinephrine. Eplerenone The serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib. Eravacycline The serum concentration of Eravacycline can be decreased when it is combined with Dabrafenib. Erdafitinib The metabolism of Erdafitinib can be increased when combined with Dabrafenib. Ergoloid mesylate The serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib. Ergometrine The serum concentration of Ergometrine can be decreased when it is combined with Dabrafenib. Ergotamine The serum concentration of Dabrafenib can be increased when it is combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dabrafenib. Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib. Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Dabrafenib. Erythromycin The serum concentration of Erythromycin can be decreased when it is combined with Dabrafenib. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dabrafenib. Escitalopram The serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib. Esketamine The serum concentration of Esketamine can be decreased when it is combined with Dabrafenib. Eslicarbazepine The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine. Eslicarbazepine The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine acetate. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dabrafenib. Esomeprazole The serum concentration of Esomeprazole can be decreased when it is combined with Dabrafenib. Estazolam The serum concentration of Estazolam can be decreased when it is combined with Dabrafenib. Esterified estrogens The serum concentration of Esterified estrogens can be decreased when it is combined with Dabrafenib. Estetrol The serum concentration of Estetrol can be decreased when it is combined with Dabrafenib. Estradiol The serum concentration of Estradiol can be decreased when it is combined with Dabrafenib. Estradiol acetate The serum concentration of Estradiol acetate can be decreased when it is combined with Dabrafenib. Estradiol benzoate The serum concentration of Estradiol benzoate can be decreased when it is combined with Dabrafenib. Estradiol cypionate The serum concentration of Estradiol cypionate can be decreased when it is combined with Dabrafenib. Estradiol dienanthate The serum concentration of Estradiol dienanthate can be decreased when it is combined with Dabrafenib. Estradiol valerate The serum concentration of Estradiol valerate can be decreased when it is combined with Dabrafenib. Estramustine The serum concentration of Estramustine can be decreased when it is combined with Dabrafenib. Estrone The serum concentration of Estrone can be decreased when it is combined with Dabrafenib. Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Dabrafenib. Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib. Etanercept The metabolism of Dabrafenib can be increased when combined with Etanercept. Ethambutol The metabolism of Dabrafenib can be decreased when combined with Ethambutol. Ethanol The serum concentration of Ethanol can be decreased when it is combined with Dabrafenib. Ethinylestradiol The serum concentration of Ethinylestradiol can be decreased when it is combined with Dabrafenib. Ethosuximide The serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Ethyl chloride. Ethynodiol The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Dabrafenib. Etidocaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Etidocaine. Etodolac The serum concentration of Etodolac can be decreased when it is combined with Dabrafenib. Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Dabrafenib. Etoposide The serum concentration of Etoposide can be decreased when it is combined with Dabrafenib. Etoricoxib The serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib. Etravirine The serum concentration of Etravirine can be decreased when it is combined with Dabrafenib. Everolimus The serum concentration of Everolimus can be decreased when it is combined with Dabrafenib. Exemestane The serum concentration of Exemestane can be decreased when it is combined with Dabrafenib. Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Dabrafenib. Ezetimibe Dabrafenib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Dabrafenib. Famotidine Famotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Favipiravir The serum concentration of Dabrafenib can be increased when it is combined with Favipiravir. Febuxostat The excretion of Dabrafenib can be decreased when combined with Febuxostat. Fedratinib The serum concentration of Fedratinib can be decreased when it is combined with Dabrafenib. Felbamate The serum concentration of Felbamate can be decreased when it is combined with Dabrafenib. Felodipine The serum concentration of Dabrafenib can be increased when it is combined with Felodipine. Fenfluramine The serum concentration of Fenfluramine can be decreased when it is combined with Dabrafenib. Fenofibrate The serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib. Fentanyl The metabolism of Fentanyl can be decreased when combined with Dabrafenib. Fesoterodine The serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib. Fexinidazole The serum concentration of Fexinidazole can be decreased when it is combined with Dabrafenib. Fexofenadine The excretion of Fexofenadine can be decreased when combined with Dabrafenib. Filgotinib The serum concentration of Dabrafenib can be increased when it is combined with Filgotinib. Finasteride The serum concentration of Finasteride can be decreased when it is combined with Dabrafenib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Dabrafenib. Fish oil The serum concentration of Fish oil can be decreased when it is combined with Dabrafenib. Flecainide The metabolism of Dabrafenib can be decreased when combined with Flecainide. Flibanserin The serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib. Floxuridine The metabolism of Dabrafenib can be decreased when combined with Floxuridine. Flucloxacillin The metabolism of Dabrafenib can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Dabrafenib can be increased when it is combined with Fluconazole. Fludrocortisone The serum concentration of Fludrocortisone can be decreased when it is combined with Dabrafenib. Fluindione The serum concentration of Fluindione can be decreased when it is combined with Dabrafenib. Flumethasone The serum concentration of Flumethasone can be decreased when it is combined with Dabrafenib. Flunarizine The serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib. Flunisolide The serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib. Flunitrazepam The serum concentration of Flunitrazepam can be decreased when it is combined with Dabrafenib. Fluocinolone acetonide The serum concentration of Fluocinolone acetonide can be decreased when it is combined with Dabrafenib. Fluocinonide The serum concentration of Fluocinonide can be decreased when it is combined with Dabrafenib. Fluocortolone The serum concentration of Fluocortolone can be decreased when it is combined with Dabrafenib. Fluorescein The excretion of Fluorescein can be decreased when combined with Dabrafenib. Fluorometholone The serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib. Fluorouracil The serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib. Fluoxetine The serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib. Flupentixol The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Flupentixol. Fluprednisolone The serum concentration of Fluprednisolone can be decreased when it is combined with Dabrafenib. Flurandrenolide The serum concentration of Flurandrenolide can be decreased when it is combined with Dabrafenib. Flurazepam The serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib. Flurbiprofen The serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib. Fluspirilene The serum concentration of Fluspirilene can be decreased when it is combined with Dabrafenib. Flutamide The serum concentration of Flutamide can be decreased when it is combined with Dabrafenib. Fluticasone The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone. Fluticasone furoate The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone furoate. Fluticasone propionate The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone propionate. Fluvastatin The serum concentration of Fluvastatin can be decreased when it is combined with Dabrafenib. Fluvoxamine The serum concentration of Fluvoxamine can be decreased when it is combined with Dabrafenib. Folic acid Dabrafenib may decrease the excretion rate of Folic acid which could result in a higher serum level. Formestane The metabolism of Dabrafenib can be increased when combined with Formestane. Formoterol The serum concentration of Formoterol can be decreased when it is combined with Dabrafenib. Fosamprenavir The serum concentration of Fosamprenavir can be decreased when it is combined with Dabrafenib. Fosaprepitant The serum concentration of Fosaprepitant can be decreased when it is combined with Dabrafenib. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dabrafenib. Fosnetupitant The serum concentration of Fosnetupitant can be decreased when it is combined with Dabrafenib. Fosphenytoin The serum concentration of Fosphenytoin can be decreased when it is combined with Dabrafenib. Fostamatinib The serum concentration of Fostamatinib can be decreased when it is combined with Dabrafenib. Fostemsavir The serum concentration of Fostemsavir can be decreased when it is combined with Dabrafenib. Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Dabrafenib. Furosemide The metabolism of Furosemide can be decreased when combined with Dabrafenib. Fusidic acid The serum concentration of Fusidic acid can be decreased when it is combined with Dabrafenib. Futibatinib The serum concentration of Futibatinib can be decreased when it is combined with Dabrafenib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Gadobenic acid. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Dabrafenib. Galantamine The serum concentration of Galantamine can be decreased when it is combined with Dabrafenib. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dabrafenib. Gefitinib The serum concentration of Gefitinib can be decreased when it is combined with Dabrafenib. Gemcitabine The serum concentration of Dabrafenib can be increased when it is combined with Gemcitabine. Gemfibrozil The serum concentration of Dabrafenib can be increased when it is combined with Gemfibrozil. Gemifloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Gemifloxacin. Gentamicin The serum concentration of Gentamicin can be increased when it is combined with Dabrafenib. Gestrinone The serum concentration of Gestrinone can be decreased when it is combined with Dabrafenib. Gilteritinib The serum concentration of Gilteritinib can be decreased when it is combined with Dabrafenib. Ginkgo biloba The metabolism of Dabrafenib can be decreased when combined with Ginkgo biloba. Glasdegib The serum concentration of Glasdegib can be decreased when it is combined with Dabrafenib. Glecaprevir The serum concentration of Dabrafenib can be increased when it is combined with Glecaprevir. Gliclazide The serum concentration of Gliclazide can be decreased when it is combined with Dabrafenib. Glimepiride The serum concentration of Glimepiride can be decreased when it is combined with Dabrafenib. Glipizide The serum concentration of Glipizide can be decreased when it is combined with Dabrafenib. Gliquidone The serum concentration of Gliquidone can be decreased when it is combined with Dabrafenib. Glyburide The serum concentration of Glyburide can be decreased when it is combined with Dabrafenib. Glycerol phenylbutyrate The metabolism of Dabrafenib can be increased when combined with Glycerol phenylbutyrate. Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Dabrafenib. Golimumab The metabolism of Dabrafenib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin. Granisetron The serum concentration of Granisetron can be decreased when it is combined with Dabrafenib. Grazoprevir The serum concentration of Grazoprevir can be decreased when it is combined with Dabrafenib. Grepafloxacin The serum concentration of Grepafloxacin can be decreased when it is combined with Dabrafenib. Griseofulvin The metabolism of Dabrafenib can be increased when combined with Griseofulvin. Guanfacine The serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib. Halcinonide The serum concentration of Halcinonide can be decreased when it is combined with Dabrafenib. Halofantrine The serum concentration of Halofantrine can be decreased when it is combined with Dabrafenib. Haloperidol The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol. Halothane The serum concentration of Halothane can be decreased when it is combined with Dabrafenib. Histamine The serum concentration of Histamine can be increased when it is combined with Dabrafenib. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Dabrafenib. Hydralazine The metabolism of Dabrafenib can be decreased when combined with Hydralazine. Hydrochlorothiazide The excretion of Hydrochlorothiazide can be decreased when combined with Dabrafenib. Hydrocodone The serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib. Hydrocortamate The metabolism of Dabrafenib can be increased when combined with Hydrocortamate. Hydrocortisone The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib. Hydrocortisone acetate The serum concentration of Hydrocortisone acetate can be decreased when it is combined with Dabrafenib. Hydrocortisone The serum concentration of Hydrocortisone butyrate can be decreased when it is combined with Dabrafenib. Hydrocortisone The serum concentration of Hydrocortisone cypionate can be decreased when it is combined with Dabrafenib. Hydrocortisone The serum concentration of Hydrocortisone phosphate can be decreased when it is combined with Dabrafenib. Hydrocortisone The serum concentration of Hydrocortisone probutate can be decreased when it is combined with Dabrafenib. Hydrocortisone The serum concentration of Hydrocortisone succinate can be decreased when it is combined with Dabrafenib. Hydrocortisone The serum concentration of Hydrocortisone valerate can be decreased when it is combined with Dabrafenib. Hydromorphone The serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib. Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Hydroxychloroquine The serum concentration of Hydroxychloroquine can be decreased when it is combined with Dabrafenib. Hydroxyprogesterone The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dabrafenib. Hydroxyzine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dabrafenib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib. Ibrexafungerp The serum concentration of Ibrexafungerp can be decreased when it is combined with Dabrafenib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Dabrafenib. Ibuprofen The serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib. Ibutilide The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ibutilide. Idarubicin The serum concentration of Idarubicin can be decreased when it is combined with Dabrafenib. Idelalisib The serum concentration of Idelalisib can be decreased when it is combined with Dabrafenib. Ifosfamide The metabolism of Ifosfamide can be increased when combined with Dabrafenib. Iloperidone The metabolism of Iloperidone can be decreased when combined with Dabrafenib. Imatinib The serum concentration of Imatinib can be decreased when it is combined with Dabrafenib. Imipramine The serum concentration of Imipramine can be decreased when it is combined with Dabrafenib. Imiquimod The serum concentration of Imiquimod can be decreased when it is combined with Dabrafenib. Indacaterol The serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib. Indapamide The serum concentration of Indapamide can be decreased when it is combined with Dabrafenib. Indinavir The serum concentration of Dabrafenib can be increased when it is combined with Indinavir. Indomethacin The serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib. Infigratinib The serum concentration of Infigratinib can be decreased when it is combined with Dabrafenib. Infliximab The metabolism of Dabrafenib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Inotersen. Inotuzumab The serum concentration of Dabrafenib can be increased when it is combined with Inotuzumab ozogamicin. Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Dabrafenib. Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Dabrafenib. Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Dabrafenib. Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Dabrafenib. Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Dabrafenib. Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Dabrafenib. Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib. Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Dabrafenib. Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib. Ipecac The serum concentration of Ipecac can be decreased when it is combined with Dabrafenib. Irbesartan The serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib. Irinotecan The risk or severity of neutropenia can be increased when Dabrafenib is combined with Irinotecan. Isavuconazole The serum concentration of Isavuconazole can be decreased when it is combined with Dabrafenib. Isavuconazonium The serum concentration of Isavuconazonium can be decreased when it is combined with Dabrafenib. Isoflurane The serum concentration of Isoflurane can be decreased when it is combined with Dabrafenib. Isoniazid The metabolism of Dabrafenib can be decreased when combined with Isoniazid. Isotretinoin The serum concentration of Isotretinoin can be decreased when it is combined with Dabrafenib. Isradipine The serum concentration of Isradipine can be decreased when it is combined with Dabrafenib. Istradefylline The serum concentration of Istradefylline can be decreased when it is combined with Dabrafenib. Itraconazole The serum concentration of Dabrafenib can be increased when it is combined with Itraconazole. Ivabradine The serum concentration of Ivabradine can be decreased when it is combined with Dabrafenib. Ivacaftor The serum concentration of Ivacaftor can be decreased when it is combined with Dabrafenib. Ivermectin The serum concentration of Ivermectin can be decreased when it is combined with Dabrafenib. Ivosidenib The metabolism of Dabrafenib can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Ixabepilone can be decreased when it is combined with Dabrafenib. Ixazomib The serum concentration of Ixazomib can be decreased when it is combined with Dabrafenib. Ketamine The serum concentration of Ketamine can be decreased when it is combined with Dabrafenib. Ketazolam The serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib. Ketoconazole The serum concentration of Dabrafenib can be increased when it is combined with Ketoconazole. Ketoprofen The metabolism of Dabrafenib can be decreased when combined with Ketoprofen. Ketorolac The serum concentration of Ketorolac can be decreased when it is combined with Dabrafenib. Labetalol The serum concentration of Labetalol can be decreased when it is combined with Dabrafenib. Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Dabrafenib. Lacosamide The serum concentration of Lacosamide can be decreased when it is combined with Dabrafenib. Lamivudine Dabrafenib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Dabrafenib. Lanreotide The metabolism of Dabrafenib can be decreased when combined with Lanreotide. Lansoprazole The serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib. Lapatinib The serum concentration of Lapatinib can be decreased when it is combined with Dabrafenib. Larotrectinib The serum concentration of Larotrectinib can be decreased when it is combined with Dabrafenib. Lasmiditan The serum concentration of Dabrafenib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Dabrafenib can be increased when it is combined with Ledipasvir. Lefamulin Lefamulin may increase the QTc-prolonging activities of Dabrafenib. Leflunomide The serum concentration of Leflunomide can be decreased when it is combined with Dabrafenib. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Dabrafenib. Lenvatinib Dabrafenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. You Might Also Read Tretinoin Acne Tropical Creams - Uses, Indications Lercanidipine The serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib. Lesinurad The serum concentration of Lesinurad can be decreased when it is combined with Dabrafenib. Letermovir The metabolism of Dabrafenib can be decreased when combined with Letermovir. Letrozole The serum concentration of Letrozole can be decreased when it is combined with Dabrafenib. Leucovorin The excretion of Leucovorin can be decreased when combined with Dabrafenib. Leuprolide The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide. Levacetylmethadol The serum concentration of Levacetylmethadol can be decreased when it is combined with Dabrafenib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Dabrafenib. Levobupivacaine The serum concentration of Levobupivacaine can be decreased when it is combined with Dabrafenib. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dabrafenib. Levocarnitine The excretion of Levocarnitine can be decreased when combined with Dabrafenib. Levocetirizine The serum concentration of Levocetirizine can be decreased when it is combined with Dabrafenib. Levofloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levofloxacin. Levoketoconazole The serum concentration of Dabrafenib can be increased when it is combined with Levoketoconazole. Levomenthol The serum concentration of Levomenthol can be decreased when it is combined with Dabrafenib. Levomilnacipran The serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib. Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Dabrafenib. Levosalbutamol The excretion of Levosalbutamol can be decreased when combined with Dabrafenib. Levosimendan The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levosimendan. Levothyroxine The serum concentration of Dabrafenib can be decreased when it is combined with Levothyroxine. Lidocaine The serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib. Lidoflazine The serum concentration of Lidoflazine can be decreased when it is combined with Dabrafenib. Linagliptin The serum concentration of Linagliptin can be decreased when it is combined with Dabrafenib. Linzagolix The serum concentration of Dabrafenib can be increased when it is combined with Linzagolix. Liothyronine The metabolism of Liothyronine can be decreased when combined with Dabrafenib. Liotrix The serum concentration of Liotrix can be decreased when it is combined with Dabrafenib. Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Dabrafenib. Lisuride The serum concentration of Lisuride can be decreased when it is combined with Dabrafenib. Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Dabrafenib. Lofexidine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lofexidine. Lomefloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lomefloxacin. Lomitapide The serum concentration of Lomitapide can be decreased when it is combined with Dabrafenib. Lonafarnib The serum concentration of Lonafarnib can be increased when it is combined with Dabrafenib. Loncastuximab The serum concentration of Dabrafenib can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Loperamide can be decreased when it is combined with Dabrafenib. Lopinavir The serum concentration of Dabrafenib can be increased when it is combined with Lopinavir. Loratadine The serum concentration of Loratadine can be decreased when it is combined with Dabrafenib. Lorazepam The serum concentration of Lorazepam can be decreased when it is combined with Dabrafenib. Lorcaserin The serum concentration of Lorcaserin can be decreased when it is combined with Dabrafenib. Lorlatinib The serum concentration of Lorlatinib can be decreased when it is combined with Dabrafenib. Lornoxicam The serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib. Lorpiprazole The serum concentration of Lorpiprazole can be decreased when it is combined with Dabrafenib. Losartan The serum concentration of Losartan can be decreased when it is combined with Dabrafenib. Lovastatin The metabolism of Lovastatin can be decreased when combined with Dabrafenib. Loxapine The serum concentration of Dabrafenib can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Dabrafenib can be decreased when it is combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be decreased when it is combined with Dabrafenib. Lumefantrine The serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib. Lumiracoxib The serum concentration of Lumiracoxib can be decreased when it is combined with Dabrafenib. Lurasidone The serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib. Lurbinectedin The serum concentration of Lurbinectedin can be decreased when it is combined with Dabrafenib. Lusutrombopag Dabrafenib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Lynestrenol The serum concentration of Lynestrenol can be decreased when it is combined with Dabrafenib. Macimorelin The serum concentration of Macimorelin can be decreased when it is combined with Dabrafenib. Macitentan The serum concentration of Macitentan can be decreased when it is combined with Dabrafenib. Magaldrate Magaldrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium trisilicate Magnesium trisilicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Malathion The serum concentration of Malathion can be decreased when it is combined with Dabrafenib. Manidipine The serum concentration of Manidipine can be decreased when it is combined with Dabrafenib. Mannitol The serum concentration of Dabrafenib can be increased when it is combined with Mannitol. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dabrafenib. Maraviroc The serum concentration of Maraviroc can be decreased when it is combined with Dabrafenib. Maribavir The serum concentration of Maribavir can be decreased when it is combined with Dabrafenib. Mavacamten The serum concentration of Mavacamten can be decreased when it is combined with Dabrafenib. Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Dabrafenib. Medrogestone The serum concentration of Medrogestone can be decreased when it is combined with Dabrafenib. Medroxyprogesterone The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib. Medrysone The serum concentration of Medrysone can be decreased when it is combined with Dabrafenib. Mefenamic acid The serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib. Mefloquine The serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib. Megestrol acetate The serum concentration of Megestrol acetate can be decreased when it is combined with Dabrafenib. Meloxicam The serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib. Memantine The serum concentration of Memantine can be increased when it is combined with Dabrafenib. Meperidine The serum concentration of Meperidine can be decreased when it is combined with Dabrafenib. Mephenytoin The serum concentration of Mephenytoin can be decreased when it is combined with Dabrafenib. Mepivacaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Mepivacaine. Meprednisone The serum concentration of Meprednisone can be decreased when it is combined with Dabrafenib. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Dabrafenib. Mercaptopurine The excretion of Mercaptopurine can be decreased when combined with Dabrafenib. Mesoridazine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mesoridazine. Mestranol The serum concentration of Mestranol can be decreased when it is combined with Dabrafenib. Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib. Methadone The serum concentration of Methadone can be decreased when it is combined with Dabrafenib. Methantheline Methantheline can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Methimazole The serum concentration of Dabrafenib can be increased when it is combined with Methimazole. Methotrexate The serum concentration of Methotrexate can be decreased when it is combined with Dabrafenib. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Dabrafenib. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dabrafenib. Methoxyflurane The serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib. Methsuximide The serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib. Methylene blue The serum concentration of Methylene blue can be decreased when it is combined with Dabrafenib. Methylergometrine The serum concentration of Methylergometrine can be decreased when it is combined with Dabrafenib. Methylphenobarbital The serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib. Methylprednisolone The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib. Methylprednisone The serum concentration of Methylprednisone can be decreased when it is combined with Dabrafenib. Methyltestosterone The serum concentration of Methyltestosterone can be decreased when it is combined with Dabrafenib. Methysergide The serum concentration of Methysergide can be decreased when it is combined with Dabrafenib. Metoclopramide The serum concentration of Metoclopramide can be decreased when it is combined with Dabrafenib. Metreleptin The metabolism of Dabrafenib can be increased when combined with Metreleptin. Metronidazole The metabolism of Dabrafenib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Dabrafenib can be increased when combined with Metyrapone. Mexiletine The serum concentration of Mexiletine can be decreased when it is combined with Dabrafenib. Mianserin The serum concentration of Mianserin can be decreased when it is combined with Dabrafenib. Miconazole The metabolism of Dabrafenib can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be decreased when it is combined with Dabrafenib. Midostaurin The serum concentration of Dabrafenib can be increased when it is combined with Midostaurin. Mifepristone The serum concentration of Dabrafenib can be increased when it is combined with Mifepristone. Migalastat The metabolism of Migalastat can be decreased when combined with Dabrafenib. Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Dabrafenib. Milnacipran The serum concentration of Milnacipran can be decreased when it is combined with Dabrafenib. Minoxidil The metabolism of Minoxidil can be decreased when combined with Dabrafenib. Miocamycin The metabolism of Dabrafenib can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib. Mirtazapine The serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib. Mitapivat The serum concentration of Mitapivat can be decreased when it is combined with Dabrafenib. Mitotane The serum concentration of Dabrafenib can be decreased when it is combined with Mitotane. Mitoxantrone Dabrafenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mizolastine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mobocertinib. Moclobemide The serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib. Modafinil The serum concentration of Modafinil can be decreased when it is combined with Dabrafenib. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dabrafenib. Mometasone furoate The serum concentration of Dabrafenib can be increased when it is combined with Mometasone furoate. Montelukast The serum concentration of Montelukast can be decreased when it is combined with Dabrafenib. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Dabrafenib. Morphine The serum concentration of Morphine can be decreased when it is combined with Dabrafenib. Mosunetuzumab The metabolism of Dabrafenib can be decreased when combined with Mosunetuzumab. Moxifloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Moxifloxacin. Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib. Mycophenolic acid The metabolism of Mycophenolic acid can be decreased when combined with Dabrafenib. Nabilone The serum concentration of Nabilone can be decreased when it is combined with Dabrafenib. Nabumetone The serum concentration of Nabumetone can be decreased when it is combined with Dabrafenib. Nafcillin The metabolism of Dabrafenib can be increased when combined with Nafcillin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Nalidixic acid. Naloxegol The serum concentration of Naloxegol can be decreased when it is combined with Dabrafenib. Naloxone The serum concentration of Dabrafenib can be increased when it is combined with Naloxone. Naltrexone The metabolism of Naltrexone can be decreased when combined with Dabrafenib. Naproxen The serum concentration of Naproxen can be decreased when it is combined with Dabrafenib. Nateglinide The serum concentration of Nateglinide can be decreased when it is combined with Dabrafenib. Nebivolol The serum concentration of Nebivolol can be decreased when it is combined with Dabrafenib. Nefazodone The serum concentration of Dabrafenib can be increased when it is combined with Nefazodone. Nelfinavir The serum concentration of Dabrafenib can be increased when it is combined with Nelfinavir. Neratinib The serum concentration of Neratinib can be decreased when it is combined with Dabrafenib. Netupitant The serum concentration of Netupitant can be decreased when it is combined with Dabrafenib. Nevirapine The serum concentration of Nevirapine can be decreased when it is combined with Dabrafenib. Niacin The metabolism of Dabrafenib can be decreased when combined with Niacin. Nicardipine The serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib. Niclosamide The serum concentration of Niclosamide can be decreased when it is combined with Dabrafenib. Nicotine The serum concentration of Nicotine can be decreased when it is combined with Dabrafenib. Nifedipine The serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib. Nilotinib The serum concentration of Dabrafenib can be increased when it is combined with Nilotinib. Nilutamide The serum concentration of Nilutamide can be decreased when it is combined with Dabrafenib. Nilvadipine The serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib. Nimesulide The serum concentration of Nimesulide can be decreased when it is combined with Dabrafenib. Nimodipine The serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib. Nintedanib The serum concentration of Nintedanib can be decreased when it is combined with Dabrafenib. Nirmatrelvir The serum concentration of Nirmatrelvir can be decreased when it is combined with Dabrafenib. Nisoldipine The serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib. Nitrazepam The serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib. Nitrendipine The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib. Nitrofurantoin Dabrafenib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nizatidine Nizatidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Nomegestrol The serum concentration of Nomegestrol can be decreased when it is combined with Dabrafenib. Nomegestrol acetate The serum concentration of Nomegestrol acetate can be decreased when it is combined with Dabrafenib. Norelgestromin The serum concentration of Norelgestromin can be decreased when it is combined with Dabrafenib. Norepinephrine The serum concentration of Norepinephrine can be increased when it is combined with Dabrafenib. Norethisterone The serum concentration of Norethisterone can be decreased when it is combined with Dabrafenib. Norethynodrel The serum concentration of Norethynodrel can be decreased when it is combined with Dabrafenib. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dabrafenib. Norgestimate The serum concentration of Norgestimate can be decreased when it is combined with Dabrafenib. Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Dabrafenib. Nortriptyline The serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib. Noscapine The metabolism of Dabrafenib can be decreased when combined with Noscapine. Novobiocin Novobiocin may decrease the excretion rate of Dabrafenib which could result in a higher serum level. Nylidrin The serum concentration of Nylidrin can be decreased when it is combined with Dabrafenib. Octreotide The serum concentration of Dabrafenib can be increased when it is combined with Octreotide. Ofloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ofloxacin. Olanzapine Olanzapine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Olaparib The serum concentration of Olaparib can be decreased when it is combined with Dabrafenib. Oliceridine The serum concentration of Oliceridine can be decreased when it is combined with Dabrafenib. Olodaterol The serum concentration of Olodaterol can be decreased when it is combined with Dabrafenib. Omadacycline The serum concentration of Dabrafenib can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Ombitasvir can be decreased when it is combined with Dabrafenib. Omeprazole The serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib. Ondansetron The serum concentration of Ondansetron can be decreased when it is combined with Dabrafenib. Opium The serum concentration of Opium can be decreased when it is combined with Dabrafenib. Oritavancin The metabolism of Dabrafenib can be increased when combined with Oritavancin. Orphenadrine The serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib. Oseltamivir The excretion of Oseltamivir can be decreased when combined with Dabrafenib. Osilodrostat The serum concentration of Osilodrostat can be decreased when it is combined with Dabrafenib. Osimertinib The serum concentration of Osimertinib can be decreased when it is combined with Dabrafenib. Ospemifene The serum concentration of Ospemifene can be decreased when it is combined with Dabrafenib. Oteseconazole The serum concentration of Dabrafenib can be increased when it is combined with Oteseconazole. Ouabain The excretion of Ouabain can be decreased when combined with Dabrafenib. Oxaliplatin The serum concentration of Oxaliplatin can be increased when it is combined with Dabrafenib. Oxandrolone The metabolism of Dabrafenib can be decreased when combined with Oxandrolone. Oxatomide The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Oxatomide. Oxcarbazepine The metabolism of Dabrafenib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Oxybuprocaine. Oxybutynin The serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib. Oxycodone The serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib. Oxymorphone The serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib. Oxytetracycline The excretion of Oxytetracycline can be decreased when combined with Dabrafenib. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib. Ozanimod The metabolism of Ozanimod can be decreased when combined with Dabrafenib. Paclitaxel The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib. Pacritinib The serum concentration of Dabrafenib can be increased when it is combined with Pacritinib. Padeliporfin Dabrafenib may increase the photosensitizing activities of Padeliporfin. Palbociclib The serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib. Paliperidone The serum concentration of Paliperidone can be decreased when it is combined with Dabrafenib. Palonosetron The serum concentration of Palonosetron can be decreased when it is combined with Dabrafenib. Palovarotene The serum concentration of Palovarotene can be decreased when it is combined with Dabrafenib. Panobinostat The serum concentration of Panobinostat can be decreased when it is combined with Dabrafenib. Pantoprazole The serum concentration of Pantoprazole can be decreased when it is combined with Dabrafenib. Papaverine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Papaverine. Paramethadione The serum concentration of Paramethadione can be decreased when it is combined with Dabrafenib. Parecoxib The serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib. Paricalcitol The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. Paritaprevir The serum concentration of Paritaprevir can be decreased when it is combined with Dabrafenib. Paroxetine The serum concentration of Paroxetine can be decreased when it is combined with Dabrafenib. Pasireotide The metabolism of Dabrafenib can be decreased when combined with Pasireotide. Pazopanib The serum concentration of Pazopanib can be decreased when it is combined with Dabrafenib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dabrafenib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dabrafenib. Peginterferon alfa-2b The metabolism of Dabrafenib can be increased when combined with Peginterferon alfa-2b. Pemetrexed Dabrafenib may decrease the excretion rate of Pemetrexed which could result in a higher serum level. Pemigatinib The serum concentration of Pemigatinib can be decreased when it is combined with Dabrafenib. Penicillamine The excretion of Penicillamine can be decreased when combined with Dabrafenib. Pentamidine The serum concentration of Pentamidine can be decreased when it is combined with Dabrafenib. Pentobarbital The serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib. Perampanel The metabolism of Perampanel can be increased when combined with Dabrafenib. Perflutren The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Perflutren. Perhexiline The serum concentration of Perhexiline can be decreased when it is combined with Dabrafenib. Pexidartinib The metabolism of Pexidartinib can be increased when combined with Dabrafenib. Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Dabrafenib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dabrafenib. Phenobarbital The serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib. Phenol The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Phenol. Phenprocoumon The serum concentration of Phenprocoumon can be decreased when it is combined with Dabrafenib. Phentermine The serum concentration of Phentermine can be decreased when it is combined with Dabrafenib. Phenylbutazone The serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib. Phenytoin The serum concentration of Phenytoin can be decreased when it is combined with Dabrafenib. Pibrentasvir The serum concentration of Dabrafenib can be increased when it is combined with Pibrentasvir. Pimavanserin The serum concentration of Pimavanserin can be decreased when it is combined with Dabrafenib. Pimecrolimus The serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib. Pimozide The serum concentration of Pimozide can be decreased when it is combined with Dabrafenib. Pinacidil The serum concentration of Pinacidil can be decreased when it is combined with Dabrafenib. Pinaverium The serum concentration of Pinaverium can be decreased when it is combined with Dabrafenib. Pioglitazone The serum concentration of Pioglitazone can be increased when it is combined with Dabrafenib. Piperacillin The excretion of Piperacillin can be decreased when combined with Dabrafenib. Piperaquine The serum concentration of Piperaquine can be decreased when it is combined with Dabrafenib. Pipotiazine The serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib. Pirfenidone The serum concentration of Pirfenidone can be decreased when it is combined with Dabrafenib. Piroxicam The serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib. Pitavastatin The serum concentration of Pitavastatin can be decreased when it is combined with Dabrafenib. Pitolisant The serum concentration of Dabrafenib can be decreased when it is combined with Pitolisant. Polatuzumab The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Dabrafenib. Polythiazide The excretion of Polythiazide can be decreased when combined with Dabrafenib. Pomalidomide The serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib. Ponatinib The serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Dabrafenib. Porfimer sodium Dabrafenib may increase the photosensitizing activities of Porfimer sodium. Posaconazole The serum concentration of Dabrafenib can be increased when it is combined with Posaconazole. Pralatrexate Dabrafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The serum concentration of Pralsetinib can be decreased when it is combined with Dabrafenib. Pramipexole The serum concentration of Pramipexole can be increased when it is combined with Dabrafenib. Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Dabrafenib. Pramocaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Pramocaine. Prasterone The serum concentration of Prasterone can be decreased when it is combined with Dabrafenib. Prasugrel The serum concentration of Prasugrel can be decreased when it is combined with Dabrafenib. Pravastatin The excretion of Pravastatin can be decreased when combined with Dabrafenib. Prazepam The serum concentration of Prazepam can be decreased when it is combined with Dabrafenib. Praziquantel The serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib. Prazosin Dabrafenib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednicarbate The serum concentration of Prednicarbate can be decreased when it is combined with Dabrafenib. Prednisolone The serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib. Prednisolone The serum concentration of Prednisolone acetate can be decreased when it is combined with Dabrafenib. Prednisolone The serum concentration of Prednisolone phosphate can be decreased when it is combined with Dabrafenib. Prednisone The serum concentration of Prednisone can be decreased when it is combined with Dabrafenib. Prednisone acetate The metabolism of Dabrafenib can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dabrafenib. Pregnenolone The serum concentration of Pregnenolone can be decreased when it is combined with Dabrafenib. Prenylamine The serum concentration of Prenylamine can be decreased when it is combined with Dabrafenib. Pretomanid The serum concentration of Pretomanid can be decreased when it is combined with Dabrafenib. Prilocaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Prilocaine. Primaquine The serum concentration of Primaquine can be decreased when it is combined with Dabrafenib. Primidone The serum concentration of Primidone can be decreased when it is combined with Dabrafenib. Probenecid The metabolism of Dabrafenib can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Probucol. Procainamide The serum concentration of Procainamide can be increased when it is combined with Dabrafenib. Procaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Procaine. Prochlorperazine The serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib. Progesterone The serum concentration of Progesterone can be decreased when it is combined with Dabrafenib. Proguanil The serum concentration of Proguanil can be decreased when it is combined with Dabrafenib. Promazine The serum concentration of Promazine can be decreased when it is combined with Dabrafenib. You Might Also Read Zanubrutinib - Uses, Dosage, Side Effects, Interaction Promethazine The serum concentration of Promethazine can be decreased when it is combined with Dabrafenib. Propafenone The serum concentration of Propafenone can be decreased when it is combined with Dabrafenib. Proparacaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Proparacaine. Propiverine The serum concentration of Propiverine can be decreased when it is combined with Dabrafenib. Propofol The serum concentration of Propofol can be decreased when it is combined with Dabrafenib. Propoxycaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Propoxycaine. Propranolol The serum concentration of Propranolol can be decreased when it is combined with Dabrafenib. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Dabrafenib. Prucalopride The serum concentration of Prucalopride can be decreased when it is combined with Dabrafenib. Pyrimethamine The metabolism of Dabrafenib can be decreased when combined with Pyrimethamine. Quazepam The serum concentration of Quazepam can be decreased when it is combined with Dabrafenib. Quetiapine The serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib. Quinapril The excretion of Quinapril can be decreased when combined with Dabrafenib. Quinidine The serum concentration of Quinidine can be decreased when it is combined with Dabrafenib. Quinine The serum concentration of Quinine can be decreased when it is combined with Dabrafenib. Quinupristin The metabolism of Dabrafenib can be decreased when combined with Quinupristin. Rabeprazole The serum concentration of Rabeprazole can be decreased when it is combined with Dabrafenib. Raloxifene The metabolism of Dabrafenib can be decreased when combined with Raloxifene. Raltegravir The metabolism of Raltegravir can be decreased when combined with Dabrafenib. Ramelteon The serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib. Ranitidine Ranitidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ranolazine The metabolism of Ranolazine can be increased when combined with Dabrafenib. Reboxetine The serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib. Regorafenib The serum concentration of Regorafenib can be decreased when it is combined with Dabrafenib. Relebactam The excretion of Relebactam can be decreased when combined with Dabrafenib. Relugolix The serum concentration of Relugolix can be decreased when it is combined with Dabrafenib. Remdesivir The serum concentration of Remdesivir can be decreased when it is combined with Dabrafenib. Repaglinide The serum concentration of Repaglinide can be decreased when it is combined with Dabrafenib. Reserpine The serum concentration of Dabrafenib can be increased when it is combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Dabrafenib. Revefenacin Dabrafenib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The serum concentration of Dabrafenib can be increased when it is combined with Ribociclib. Rifabutin The serum concentration of Rifabutin can be decreased when it is combined with Dabrafenib. Rifampicin The serum concentration of Dabrafenib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Dabrafenib can be decreased when it is combined with Rifamycin. Rifapentine The serum concentration of Rifapentine can be decreased when it is combined with Dabrafenib. Rilonacept The metabolism of Dabrafenib can be increased when combined with Rilonacept. Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Dabrafenib. Riluzole Dabrafenib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The metabolism of Rimegepant can be increased when combined with Dabrafenib. Rimexolone The serum concentration of Rimexolone can be decreased when it is combined with Dabrafenib. Rimonabant The serum concentration of Rimonabant can be decreased when it is combined with Dabrafenib. Riociguat The serum concentration of Riociguat can be decreased when it is combined with Dabrafenib. Ripretinib The serum concentration of Ripretinib can be decreased when it is combined with Dabrafenib. Risperidone The serum concentration of Risperidone can be decreased when it is combined with Dabrafenib. Ritonavir The serum concentration of Dabrafenib can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib. Rofecoxib The serum concentration of Rofecoxib can be decreased when it is combined with Dabrafenib. Roflumilast The serum concentration of Roflumilast can be decreased when it is combined with Dabrafenib. Rolapitant The serum concentration of Rolapitant can be decreased when it is combined with Dabrafenib. Romidepsin The serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib. Ropinirole The risk or severity of adverse effects can be increased when Dabrafenib is combined with Ropinirole. Ropivacaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Ropivacaine. Rosiglitazone The serum concentration of Rosiglitazone can be decreased when it is combined with Dabrafenib. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dabrafenib. Rosuvastatin The serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib. Rotigotine The serum concentration of Rotigotine can be decreased when it is combined with Dabrafenib. Roxadustat The metabolism of Roxadustat can be decreased when combined with Dabrafenib. Roxithromycin The serum concentration of Roxithromycin can be decreased when it is combined with Dabrafenib. Rucaparib The serum concentration of Rucaparib can be decreased when it is combined with Dabrafenib. Rufinamide The metabolism of Dabrafenib can be increased when combined with Rufinamide. Rupatadine The serum concentration of Rupatadine can be decreased when it is combined with Dabrafenib. Ruxolitinib The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib. Sacituzumab govitecan The serum concentration of Sacituzumab govitecan can be increased when it is combined with Dabrafenib. Safinamide The serum concentration of Safinamide can be decreased when it is combined with Dabrafenib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dabrafenib. Salicylic acid The serum concentration of Salicylic acid can be decreased when it is combined with Dabrafenib. Salmeterol The serum concentration of Dabrafenib can be increased when it is combined with Salmeterol. Samidorphan The serum concentration of Samidorphan can be decreased when it is combined with Dabrafenib. Sapropterin The serum concentration of Dabrafenib can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Dabrafenib can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Dabrafenib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Dabrafenib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Dabrafenib can be decreased when it is combined with Satralizumab. Saxagliptin The serum concentration of Saxagliptin can be decreased when it is combined with Dabrafenib. Scopolamine The serum concentration of Scopolamine can be decreased when it is combined with Dabrafenib. Secobarbital The serum concentration of Dabrafenib can be decreased when it is combined with Secobarbital. Secukinumab The metabolism of Dabrafenib can be increased when combined with Secukinumab. Segesterone The metabolism of Segesterone acetate can be increased when combined with Dabrafenib. Selegiline The serum concentration of Selegiline can be decreased when it is combined with Dabrafenib. Selexipag The serum concentration of Selexipag can be decreased when it is combined with Dabrafenib. Selinexor The serum concentration of Selinexor can be decreased when it is combined with Dabrafenib. Selpercatinib The serum concentration of Selpercatinib can be increased when it is combined with Dabrafenib. Selumetinib The serum concentration of Selumetinib can be decreased when it is combined with Dabrafenib. Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Dabrafenib. Sertindole The serum concentration of Sertindole can be decreased when it is combined with Dabrafenib. Sertraline The serum concentration of Sertraline can be decreased when it is combined with Dabrafenib. Sevoflurane The serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib. Sibutramine The serum concentration of Sibutramine can be decreased when it is combined with Dabrafenib. Sildenafil The serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib. Silodosin The serum concentration of Silodosin can be decreased when it is combined with Dabrafenib. Siltuximab The metabolism of Dabrafenib can be increased when combined with Siltuximab. Simeprevir The serum concentration of Simeprevir can be decreased when it is combined with Dabrafenib. Simvastatin The serum concentration of Simvastatin can be decreased when it is combined with Dabrafenib. Sincalide The excretion of Sincalide can be decreased when combined with Dabrafenib. Siponimod The serum concentration of Siponimod can be decreased when it is combined with Dabrafenib. Sirolimus The serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib. Sitagliptin The serum concentration of Sitagliptin can be decreased when it is combined with Dabrafenib. Sitaxentan The serum concentration of Sitaxentan can be decreased when it is combined with Dabrafenib. Sodium Sodium bicarbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Solifenacin The serum concentration of Solifenacin can be decreased when it is combined with Dabrafenib. Solriamfetol The serum concentration of Solriamfetol can be increased when it is combined with Dabrafenib. Somatostatin The metabolism of Dabrafenib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Dabrafenib can be increased when combined with Somatrogon. Sonidegib The serum concentration of Sonidegib can be decreased when it is combined with Dabrafenib. Sorafenib The serum concentration of Dabrafenib can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Dabrafenib can be increased when it is combined with Sotagliflozin. Sotalol The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sotalol. Sotorasib The serum concentration of Dabrafenib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sparfloxacin. Spironolactone The metabolism of Dabrafenib can be decreased when combined with Spironolactone. St. John’s Wort The serum concentration of St. John’s Wort can be decreased when it is combined with Dabrafenib. Stavudine The excretion of Stavudine can be decreased when combined with Dabrafenib. Stiripentol The metabolism of Dabrafenib can be decreased when combined with Stiripentol. Succinic acid The excretion of Succinic acid can be decreased when combined with Dabrafenib. Sufentanil The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib. Sulfadiazine The serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib. Sulfamethizole The metabolism of Dabrafenib can be decreased when combined with Sulfamethizole. Sulfamethoxazole The serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib. Sulfaphenazole The metabolism of Dabrafenib can be decreased when combined with Sulfaphenazole. Sulfapyridine The metabolism of Dabrafenib can be decreased when combined with Sulfapyridine. Sulfasalazine Sulfasalazine may decrease the excretion rate of Dabrafenib which could result in a higher serum level. Sulfinpyrazone The serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib. Sulfisoxazole The metabolism of Dabrafenib can be decreased when combined with Sulfisoxazole. Sulpiride The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sulpiride. Sultopride The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sultopride. Sumatriptan Dabrafenib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib. Suprofen The serum concentration of Suprofen can be decreased when it is combined with Dabrafenib. Suvorexant The serum concentration of Suvorexant can be decreased when it is combined with Dabrafenib. Estrogens, A The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabrafenib. SEstrogens, The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dabrafenib. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Dabrafenib. Tadalafil The serum concentration of Tadalafil can be decreased when it is combined with Dabrafenib. Tafamidis The serum concentration of Dabrafenib can be increased when it is combined with Tafamidis. Talazoparib Dabrafenib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib. Tamsulosin The serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib. Tasimelteon The serum concentration of Tasimelteon can be decreased when it is combined with Dabrafenib. Taurocholic acid The excretion of Taurocholic acid can be decreased when combined with Dabrafenib. Tazarotene The serum concentration of Tazarotene can be decreased when it is combined with Dabrafenib. Tazemetostat The serum concentration of Tazemetostat can be decreased when it is combined with Dabrafenib. Tazobactam The excretion of Tazobactam can be decreased when combined with Dabrafenib. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Dabrafenib. Technetium The serum concentration of Dabrafenib can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Dabrafenib can be increased when combined with Tecovirimat. Tegafur The serum concentration of Tegafur can be decreased when it is combined with Dabrafenib. Tegaserod The metabolism of Dabrafenib can be decreased when combined with Tegaserod. Telaprevir The serum concentration of Dabrafenib can be increased when it is combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Telavancin. Telithromycin The serum concentration of Dabrafenib can be increased when it is combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Dabrafenib which could result in a higher serum level. Telotristat ethyl The serum concentration of Dabrafenib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib. Teniposide The serum concentration of Teniposide can be decreased when it is combined with Dabrafenib. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Dabrafenib. Tenofovir disoproxil The excretion of Tenofovir disoproxil can be decreased when combined with Dabrafenib. Tenoxicam The serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib. Tepotinib The serum concentration of Dabrafenib can be increased when it is combined with Tepotinib. Terbinafine The serum concentration of Terbinafine can be decreased when it is combined with Dabrafenib. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dabrafenib. Terfenadine The serum concentration of Dabrafenib can be increased when it is combined with Terfenadine. Teriflunomide The metabolism of Dabrafenib can be decreased when combined with Teriflunomide. Terlipressin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Terlipressin. Testosterone The serum concentration of Testosterone can be decreased when it is combined with Dabrafenib. Testosterone The serum concentration of Testosterone cypionate can be decreased when it is combined with Dabrafenib. Testosterone The serum concentration of Testosterone enanthate can be decreased when it is combined with Dabrafenib. Testosterone The serum concentration of Testosterone propionate can be decreased when it is combined with Dabrafenib. Tetrabenazine The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Tetracaine. Tetracycline The serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib. Tezacaftor The serum concentration of Tezacaftor can be decreased when it is combined with Dabrafenib. Thalidomide The serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib. Theophylline The serum concentration of Theophylline can be decreased when it is combined with Dabrafenib. Thiamylal The serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib. Thiopental The serum concentration of Thiopental can be decreased when it is combined with Dabrafenib. Thioridazine The serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib. Thiotepa The serum concentration of Thiotepa can be decreased when it is combined with Dabrafenib. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dabrafenib. Tiagabine The serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib. Ticagrelor The serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib. Ticlopidine The serum concentration of Ticlopidine can be decreased when it is combined with Dabrafenib. Timolol The serum concentration of Timolol can be decreased when it is combined with Dabrafenib. Tinidazole The serum concentration of Tinidazole can be decreased when it is combined with Dabrafenib. Tiotropium The serum concentration of Tiotropium can be decreased when it is combined with Dabrafenib. Tipiracil The excretion of Tipiracil can be decreased when combined with Dabrafenib. Tipranavir The serum concentration of Dabrafenib can be increased when it is combined with Tipranavir. Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Dabrafenib. Tisotumab vedotin The serum concentration of Tisotumab vedotin can be decreased when it is combined with Dabrafenib. Tivozanib The metabolism of Tivozanib can be increased when combined with Dabrafenib. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Dabrafenib. Tocilizumab The metabolism of Dabrafenib can be increased when combined with Tocilizumab. Tocofersolan The serum concentration of Tocofersolan can be decreased when it is combined with Dabrafenib. Tocopherol The serum concentration of Tocopherol can be decreased when it is combined with Dabrafenib. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Dabrafenib. Tolazamide The serum concentration of Tolazamide can be decreased when it is combined with Dabrafenib. Tolbutamide The serum concentration of Tolbutamide can be decreased when it is combined with Dabrafenib. Tolfenamic acid The serum concentration of Tolfenamic acid can be decreased when it is combined with Dabrafenib. Tolterodine The serum concentration of Tolterodine can be decreased when it is combined with Dabrafenib. Tolvaptan The serum concentration of Tolvaptan can be decreased when it is combined with Dabrafenib. Topiramate The metabolism of Dabrafenib can be increased when combined with Topiramate. Topotecan Dabrafenib may decrease the excretion rate of Topotecan which could result in a higher serum level. Torasemide The serum concentration of Torasemide can be decreased when it is combined with Dabrafenib. Toremifene The serum concentration of Toremifene can be decreased when it is combined with Dabrafenib. Trabectedin The serum concentration of Trabectedin can be decreased when it is combined with Dabrafenib. Tramadol The metabolism of Tramadol can be decreased when combined with Dabrafenib. Trametinib The risk or severity of adverse effects can be increased when Trametinib is combined with Dabrafenib. Tranylcypromine The metabolism of Dabrafenib can be decreased when combined with Tranylcypromine. Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dabrafenib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dabrafenib. Treprostinil The serum concentration of Treprostinil can be increased when it is combined with Dabrafenib. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Dabrafenib. Triamcinolone The serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib. Triazolam The serum concentration of Triazolam can be decreased when it is combined with Dabrafenib. Triclabendazole The serum concentration of Triclabendazole can be decreased when it is combined with Dabrafenib. Trifluridine The excretion of Trifluridine can be decreased when combined with Dabrafenib. Trilaciclib Dabrafenib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimebutine The serum concentration of Trimebutine can be decreased when it is combined with Dabrafenib. Trimethadione The serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib. Trimethoprim The serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib. Trimipramine The serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Dabrafenib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dabrafenib. Troglitazone The serum concentration of Troglitazone can be decreased when it is combined with Dabrafenib. Troleandomycin The serum concentration of Dabrafenib can be increased when it is combined with Troleandomycin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Trovafloxacin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Dabrafenib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Dabrafenib. Udenafil The serum concentration of Udenafil can be decreased when it is combined with Dabrafenib. Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Dabrafenib. Umbralisib The serum concentration of Dabrafenib can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Dabrafenib can be increased when it is combined with Umeclidinium. Upadacitinib The serum concentration of Upadacitinib can be decreased when it is combined with Dabrafenib. Valaciclovir The excretion of Valaciclovir can be decreased when combined with Dabrafenib. Valbenazine The serum concentration of Valbenazine can be decreased when it is combined with Dabrafenib. Valdecoxib The serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib. Valproic acid The serum concentration of Valproic acid can be decreased when it is combined with Dabrafenib. Valsartan The serum concentration of Valsartan can be decreased when it is combined with Dabrafenib. Vandetanib The serum concentration of Vandetanib can be decreased when it is combined with Dabrafenib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Dabrafenib. Varenicline The excretion of Varenicline can be decreased when combined with Dabrafenib. Velpatasvir The serum concentration of Velpatasvir can be decreased when it is combined with Dabrafenib. Vemurafenib The serum concentration of Dabrafenib can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Venetoclax can be decreased when it is combined with Dabrafenib. Venlafaxine The serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib. Verapamil The serum concentration of Verapamil can be decreased when it is combined with Dabrafenib. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Dabrafenib. Verteporfin Dabrafenib may increase the photosensitizing activities of Verteporfin. Vilanterol The serum concentration of Vilanterol can be decreased when it is combined with Dabrafenib. Vilazodone The serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib. Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dabrafenib. Viloxazine The metabolism of Dabrafenib can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be decreased when it is combined with Dabrafenib. Vincristine The serum concentration of Vincristine can be decreased when it is combined with Dabrafenib. Vindesine The serum concentration of Vindesine can be decreased when it is combined with Dabrafenib. Vinflunine The serum concentration of Vinflunine can be decreased when it is combined with Dabrafenib. Vinorelbine The serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib. Vismodegib The serum concentration of Vismodegib can be decreased when it is combined with Dabrafenib. Vitamin D The serum concentration of Vitamin D can be decreased when it is combined with Dabrafenib. Vitamin E The serum concentration of Vitamin E can be decreased when it is combined with Dabrafenib. Voclosporin The serum concentration of Dabrafenib can be increased when it is combined with Voclosporin. Vonoprazan Vonoprazan can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. Vorapaxar The serum concentration of Vorapaxar can be decreased when it is combined with Dabrafenib. Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Dabrafenib. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dabrafenib. Vortioxetine The serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib. Voxelotor The serum concentration of Dabrafenib can be increased when it is combined with Voxelotor. Voxilaprevir The serum concentration of Voxilaprevir can be decreased when it is combined with Dabrafenib. Warfarin The serum concentration of Warfarin can be decreased when it is combined with Dabrafenib. Ximelagatran The serum concentration of Ximelagatran can be decreased when it is combined with Dabrafenib. Yohimbine The serum concentration of Yohimbine can be decreased when it is combined with Dabrafenib. Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Dabrafenib. Zalcitabine The excretion of Zalcitabine can be decreased when combined with Dabrafenib. Zaleplon The serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib. Zanubrutinib The serum concentration of Zanubrutinib can be decreased when it is combined with Dabrafenib. Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib. Zileuton The serum concentration of Zileuton can be decreased when it is combined with Dabrafenib. Zimelidine The metabolism of Dabrafenib can be decreased when combined with Zimelidine. Ziprasidone The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ziprasidone. Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Dabrafenib. Zolpidem The serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib. Zonisamide The serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib. Zopiclone The serum concentration of Zopiclone can be decreased when it is combined with Dabrafenib. Zotepine The serum concentration of Zotepine can be decreased when it is combined with Dabrafenib. Zuclopenthixol The serum concentration of Zuclopenthixol can be decreased when it is combined with Dabrafenib. Drug-Food Interactions Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of dabrafenib. Avoid St. John’s Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of dabrafenib. Do not take with or immediately after a high-fat meal. Dabrafenib’s bioavailability is reduced when taken with a high-fat meal. Take on an empty stomach. Take dabrafenib at least one hour before or two hours after a meal. Pregnancy and Lactation AU TGA pregnancy category: D US FDA pregnancy category: Not assigned. Pregnancy Based on animal studies, this drug may cause fetal harm and impair fertility. This drug may decrease the efficacy of hormonal contraceptives; counsel female patients of reproductive potential to use an effective non-hormonal method of contraception during therapy and for 2 to 4 weeks after the last dose of this drug and 4 months after the last dose of trametinib when given in combination with this drug. Advise male patients of the potential risk for impaired spermatogenesis, which may be irreversible. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Lactation There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. How should this medicine be used? Dabrafenib comes as a capsule to take by mouth. It is usually taken twice a day on an empty stomach, 1 hour before or 2 hours after a meal. Take dabrafenib about 12 hours apart at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dabrafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Do not stop taking dabrafenib without talking to your doctor. Swallow the capsules whole; do not open, break, or crush them. Your doctor may adjust your dose or temporarily or permanently stop your treatment depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with dabrafenib and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. What special precautions should I follow? Before taking dabrafenib, tell your doctor and pharmacist if you are allergic to dabrafenib, any other medications, or any of the ingredients in dabrafenib capsules. Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac); dexamethasone; gemfibrozil (Lopid); ketoconazole; midazolam; nefazodone; rifampin (Rifadin, in Rifamate, in Rifater, Rimactane); and warfarin (Coumadin, Jantoven). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with dabrafenib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had diabetes; glucose-6-phosphate dehydrogenase (G6PD) deficiency (a genetic condition); bleeding problems; eye problems; heart failure or other heart problems; liver or kidney disease; or any other medical condition. tell your doctor if you are pregnant or plan to become pregnant, or if you plan to father a child. If you are female, you will need to have a pregnancy test before you start treatment, and you should use effective birth control to prevent pregnancy during your treatment and for 2 weeks after your final dose. If you are a male and your partner can become pregnant, you should use a condom while taking this medication, and for 2 weeks after your treatment, even if you have had a vasectomy (surgery to prevent sperm from leaving your body and causing pregnancy). You should know that this medication may decrease fertility in men and women; however, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. If you or your partner becomes pregnant while taking dabrafenib, call your doctor. Dabrafenib may harm the fetus. you should know that dabrafenib may decrease the effectiveness of hormonal contraceptives (birth control pills, patches, rings, implants, and injections). You should use another method of birth control to prevent pregnancy in yourself or your partner during your treatment with dabrafenib and for 2 weeks after your final dose. Talk to your doctor about birth control methods that will work for you. tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking dabrafenib and for 2 weeks after your final dose. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking dabrafenib. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Dabrafenib https://pubchem.ncbi.nlm.nih.gov/compound/Dabrafenib-mesylate https://en.wikipedia.org/wiki/Dabrafenib https://medlineplus.gov/druginfo/meds/a613038.html https://go.drugbank.com/drugs/DB08912 https://www.drugs.com/mtm/dabrafenib.htm https://www.webmd.com/drugs/2/drug-164393/dabrafenib-oral/details/list-contraindications https://www.mayoclinic.org/drugs-supplements/dabrafenib-oral-route/proper-use/drg-20061178 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Dabrafenib [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/1195765457 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DrugBank https://www.drugbank.ca/legal/terms_of_use Dabrafenib https://www.drugbank.ca/drugs/DB08912 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Dabrafenib https://comptox.epa.gov/dashboard/DTXSID20152499 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide https://echa.europa.eu/substance-information/-/substanceinfo/100.215.965 N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/221221 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking DABRAFENIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QGP4HA4G1B ChEBI Dabrafenib http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75045 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking DABRAFENIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Dabrafenib https://www.ncbi.nlm.nih.gov/books/n/livertox/Dabrafenib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82386 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=C561627 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/DABRAFENIB IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Dabrafenib http://idrblab.net/ttd/data/drug/details/D05ROI Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/405544700 European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Tafinlar (EMEA/H/C/002604) https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Dabrafenib https://www.ncbi.nlm.nih.gov/books/NBK500855/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ FDA Medication Guides https://www.fda.gov/about-fda/about-website/website-policies#linking Tafinlar https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking DABRAFENIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Dabrafenib http://www.hmdb.ca/metabolites/HMDB0250818 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Dabrafenib Mesylate https://www.cancer.gov/about-cancer/treatment/drugs/dabrafenib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html dabrafenib https://rxnav.nlm.nih.gov/id/rxnorm/1424911 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P06 PubChem https://pubchem.ncbi.nlm.nih.gov PFAS and Fluorinated Compounds in PubChem https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=35061485-726864646 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=35061485-726864646 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Dabrafenib https://www.wikidata.org/wiki/Q3011604 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html dabrafenib https://www.ncbi.nlm.nih.gov/mesh/67561627 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 Protein Kinase Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68047428 KEGG https://www.kegg.jp/kegg/legal.html Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets PATENTSCOPE (WIPO) SID 391944689 https://pubchem.ncbi.nlm.nih.gov/substance/391944689 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More